Atea Pharmaceuticals (AVIR) EBT (2019 - 2026)
Atea Pharmaceuticals' (AVIR) quarterly EBT came in at -$45.4 million in Q1 2026, down 33.23% year-on-year from -$68.0 million in Q1 2025, and up 12.09% quarter-over-quarter from -$51.6 million in Q4 2025.
Atea Pharmaceuticals (AVIR) EBT (2019 - 2026) Analysis & Trends
Atea Pharmaceuticals' EBT history runs 8 years deep, the most recent figure standing at -$45.4 million for Q1 2026.
- On a quarterly basis, EBT fell 33.23% year-over-year to -$45.4 million in Q1 2026; TTM through Mar 2026 was -$175.8 million, a 26.87% decrease from a year earlier, with the FY2025 full-year figure at -$164.5 million, up 1.76% from the prior year.
- EBT improved to -$45.4 million in Q1 2026 per AVIR's latest filing, from -$51.6 million in the prior quarter.
- Across five years, EBT topped out at -$11.9 million in Q3 2022 and bottomed at -$62.9 million in Q1 2024.
- The 5-year median for EBT is -$35.3 million (2023), against an average of -$37.2 million.
- Biggest YoY gain for EBT was 46.14% in 2022; the steepest drop was 457.19% in 2022.
- Year by year, EBT stood at -$34.3 million in 2022, then declined by 13.14% to -$38.8 million in 2023, then advanced by 14.16% to -$33.3 million in 2024, then plunged by 54.98% to -$51.6 million in 2025, then rose by 12.09% to -$45.4 million in 2026.
- Per Business Quant, the three latest AVIR EBT figures stand at -$45.4 million (Q1 2026), -$51.6 million (Q4 2025), and -$41.9 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 259.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.49 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Atea Pharmaceuticals | 376.19 Mn | 376.19 Mn | - | -45.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.39 Mn |
| Dec 31, 2025 | -51.64 Mn |
| Sep 30, 2025 | -41.85 Mn |
| Jun 30, 2025 | -36.95 Mn |
| Mar 31, 2025 | -34.07 Mn |
| Dec 31, 2024 | -33.32 Mn |
| Sep 30, 2024 | -30.93 Mn |
| Jun 30, 2024 | -40.28 Mn |
| Mar 31, 2024 | -62.94 Mn |
| Dec 31, 2023 | -38.82 Mn |
| Sep 30, 2023 | -32.92 Mn |
| Jun 30, 2023 | -27.93 Mn |
| Mar 31, 2023 | -35.27 Mn |
| Dec 31, 2022 | -34.31 Mn |
| Sep 30, 2022 | -11.90 Mn |
| Jun 30, 2022 | -31.22 Mn |
| Mar 31, 2022 | -42.08 Mn |
| Dec 31, 2021 | 121.23 Mn |
| Sep 30, 2021 | -22.09 Mn |
| Jun 30, 2021 | 8.74 Mn |